JP2017510627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510627A5 JP2017510627A5 JP2016574516A JP2016574516A JP2017510627A5 JP 2017510627 A5 JP2017510627 A5 JP 2017510627A5 JP 2016574516 A JP2016574516 A JP 2016574516A JP 2016574516 A JP2016574516 A JP 2016574516A JP 2017510627 A5 JP2017510627 A5 JP 2017510627A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- mcam
- composition according
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952835P | 2014-03-13 | 2014-03-13 | |
| US61/952,835 | 2014-03-13 | ||
| US201462023577P | 2014-07-11 | 2014-07-11 | |
| US62/023,577 | 2014-07-11 | ||
| PCT/IB2015/051785 WO2015136468A1 (en) | 2014-03-13 | 2015-03-12 | Combination treatment for multiple sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019355A Division JP2020100631A (ja) | 2014-03-13 | 2020-02-07 | 多発性硬化症の併用治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510627A JP2017510627A (ja) | 2017-04-13 |
| JP2017510627A5 true JP2017510627A5 (enExample) | 2018-04-19 |
Family
ID=52737375
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574516A Pending JP2017510627A (ja) | 2014-03-13 | 2015-03-12 | 多発性硬化症の併用治療 |
| JP2020019355A Pending JP2020100631A (ja) | 2014-03-13 | 2020-02-07 | 多発性硬化症の併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020019355A Pending JP2020100631A (ja) | 2014-03-13 | 2020-02-07 | 多発性硬化症の併用治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170002077A1 (enExample) |
| EP (1) | EP3116910A1 (enExample) |
| JP (2) | JP2017510627A (enExample) |
| KR (1) | KR20170052526A (enExample) |
| CA (1) | CA2938945A1 (enExample) |
| WO (1) | WO2015136468A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| JP6728053B2 (ja) | 2014-03-12 | 2020-07-22 | プロセナ バイオサイエンシーズ リミテッド | 抗ｍｃａｍ抗体及び関連する使用方法 |
| WO2017134178A1 (en) * | 2016-02-05 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Imaging method for predicting the onset of multiple sclerosis |
| WO2017149513A1 (en) * | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153955A1 (en) * | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| KR102931395B1 (ko) * | 2017-11-09 | 2026-02-26 | 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 | 조직 재생용 의약 및 그 제조 방법 |
| EP3996747A4 (en) * | 2019-07-11 | 2023-08-16 | Tavotek Biotherapeutics (Hong Kong) Limited | AGENTS THAT INTERFERE WITH THYMIC STROMAL LYMPHOPOIETIN RECEPTOR (TSLP) SIGNALING |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CA2291762A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
| JP2001512138A (ja) | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Ｖｌａ−４が介在する白血球付着を阻害するベンジル化合物 |
| EP1001972A1 (en) | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| WO1999006432A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| CN100369888C (zh) | 1997-08-22 | 2008-02-20 | 霍夫曼-拉罗奇有限公司 | 芳酰基苯丙氨酸衍生物 |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| BR9909625A (pt) | 1998-04-16 | 2002-01-15 | Texas Biotechnology Corp | Amidas n,n-di-substituìdas que inibem a ligação de integrinas a seus receptores |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821406D0 (en) | 1998-10-01 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
| MXPA01007845A (es) | 1999-02-05 | 2004-06-22 | Samsung Electronics Co Ltd | Metodo para la recuperacion de la textura de imagenes y aparato para el mismo. |
| NZ515248A (en) | 1999-05-07 | 2004-01-30 | Texas Biotechnology Corp | Heterocyclic substituted carboxylic acid derivatives useful for inhibit the binding of integrins to their receptors |
| WO2001014328A2 (en) | 1999-08-20 | 2001-03-01 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| US6689781B2 (en) | 2000-07-21 | 2004-02-10 | Elan Pharmaceuticals, Inc. | Phenylalanine derivatives as alpha 4 integrin inhibitors |
| US7192931B2 (en) * | 2000-10-12 | 2007-03-20 | Neuren Pharmaceuticals Ltd. | Treatment of demyelinating diseases |
| AU2002233340B2 (en) * | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| US7361679B2 (en) | 2001-09-12 | 2008-04-22 | Kaken Pharmaceutical Co., Ltd. | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
| US7576101B2 (en) * | 2003-01-24 | 2009-08-18 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| ES2707815T3 (es) * | 2007-06-14 | 2019-04-05 | Biogen Ma Inc | Formulaciones de anticuerpo natalizumab |
| EP2588123A2 (en) * | 2010-06-30 | 2013-05-08 | Compugen Ltd. | C1orf32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| WO2012170071A1 (en) | 2011-06-06 | 2012-12-13 | Elan Pharmaceuticas, Inc | Mcam antagonists and methods of treatment |
| TWI660972B (zh) * | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
-
2015
- 2015-03-12 JP JP2016574516A patent/JP2017510627A/ja active Pending
- 2015-03-12 EP EP15712195.5A patent/EP3116910A1/en not_active Withdrawn
- 2015-03-12 US US15/125,568 patent/US20170002077A1/en not_active Abandoned
- 2015-03-12 CA CA2938945A patent/CA2938945A1/en active Pending
- 2015-03-12 WO PCT/IB2015/051785 patent/WO2015136468A1/en not_active Ceased
- 2015-03-12 KR KR1020167027876A patent/KR20170052526A/ko not_active Abandoned
-
2020
- 2020-02-07 JP JP2020019355A patent/JP2020100631A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510627A5 (enExample) | ||
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| HRP20241447T1 (hr) | Bispecifična inhibitor antitijela kontrolnih točaka | |
| HRP20190643T1 (hr) | Protutijela protiv dkk-1 | |
| HRP20201729T1 (hr) | Antitijela protiv aktivina a i njihova primjena | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| RU2018119686A (ru) | Антитела и фрагменты антител для сайт-специфического конъюгирования | |
| JP2014205674A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| JP2016536322A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2016029056A5 (enExample) | ||
| MY173334A (en) | Antibodies that bind to tl1a and their uses | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| RU2017113732A (ru) | Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii) | |
| JP2016512214A5 (enExample) | ||
| HRP20220069T1 (hr) | Antitijelo | |
| JP2015509960A5 (enExample) | ||
| JP2014527396A5 (enExample) | ||
| JP2017511152A5 (enExample) | ||
| JP2014518198A5 (enExample) | ||
| JP2017536821A5 (enExample) |